Sun Pharma reported a 40% year-on-year (YoY) jump in net profit to Rs 2,836 crore in Q1FY25 led by higher sales growth in domestic formulat...

A 2019 study published by the Indian Journal of Gastroenterology revealed that the prevalence of GERD in the Indian population is around 8....

Sun Pharmaceutical Industries expects high single-digit top line growth in FY24 with total revenue at Rs 48,497 crore, led by Managing Dire...

Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend o...

Sun Pharma on Wednesday reported a 16.5% year-on-year (YoY) jump in net profit to Rs 2524 crore in Q3FY24 led by broad-based growth, includ...

The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 7.5% to Rs. 3179.4 crore in Q2, and EBITDA margins declined 90...

Sun Pharma Q1FY24 net profit fell 2% YoY to Rs 2023 crore due to exceptional items worth Rs 323 crore. However, excluding exceptional items...

Sun Pharma posted a net profit of INR 1,985 crore ($266m) in Q4 FY23 due to increased specialty drug sales and strong growth in domestic fo...

Industry executives and headhunters told ET that salesforce is needed as they launch more products targeting chronic therapeutic segments s...

Both companies entered into partnership for the sales and co-marketing of Empagliflozin and its combinations including Cospiaq (Empaglifloz...

As part of the strategy to stay ahead of its rivals in the highly fragmented domestic formulation business, Sun Pharma has embarked on majo...

The revival was on the back of therapies, including cardiac and anti-diabetic, which grew by 19.5% and 9.7% respectively in October (over S...

Drug firm Zydus Cadila on Thursday said it is launching pressurized metered dose inhaler for patients suffering from Chronic Obstructive Pu...

Insulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-sell...

The robust growth in July was attributed to nine therapies having outgrown the pharma market, with the anti-diabetic market growing at 25.4...

In a grim reminder of the rise of lifestyle diseases, anti-diabetic molecule has for the first time become the largest-selling formulation ...

In the wake of a government ban on top-selling diabetes drug, pioglitazone , the volumes are expected to shift to other classes such as fir...